No Data
No Data
imeik technology development (300896.SZ): Simei Geru peptide injection obtained the drug clinical trial approval notice.
Grain Granville on October 14th │ imeik technology development (300896.SZ) announced that its wholly-owned subsidiary, Beijing Nobot Biotechnology Co., Ltd. (referred to as "Nebot Biotechnology"), recently received the State Food and Drug Administration's approved and issued the "Drug Clinical Trial Approval Notice" for Simgegrupeptide Injection, and will start clinical trials in the near future. Weight management is one of the main projects in non-surgical medical beauty. The research and development product Simgegru peptide injection is a GLP-1 analogue. As an iterative product of Liraglutide injection, it has significant effects on weight management and can meet the needs of obese patients for weight loss.
Imeik Technology Development (300896.SZ): obtained a medical instruments registration certificate.
On October 9th, Gelunhui (300896.SZ) announced that it received a medical instruments registration certificate issued by the National Medical Products Administration on October 9, 2024. The product is named as cross-linked hyaluronic acid sodium gel containing polyethylene glycol microspheres for adult subcutaneous injection to improve mild to moderate chin retraction. The acquisition of the above product's medical instruments registration certificate enriches the company's product categories and enhances the company's core competitiveness.
Imeik Technology Development Co.,Ltd.'s (SZSE:300896) Shares Climb 63% But Its Business Is Yet to Catch Up
Founder Securities: Comprehensive policy efforts, focus on pro-cyclical sectors
Main theme of beauty and skincare: Policies are fully implemented, and the beauty and skincare sector is expected to benefit first.
An Intrinsic Calculation For Imeik Technology Development Co.,Ltd. (SZSE:300896) Suggests It's 50% Undervalued
imeik technology development (300896.SZ): The growth logic remains the same, and the product expansion strategy outlines the long-term growth blueprint.
In recent years, the medical beauty industry has taken the lead in the capital markets with its high prosperity, and there is a consensus in the market on the long-term positive trend of the medical beauty industry. After going through the dual test of consumer suppression during the pandemic and the gradual recovery of the economy, according to the "China Medical Beauty Industry 2024 Deep Insight Report," 2024 will be a key turning point in the medical beauty field: it will be a new stage where the consumer market transitions from stable recovery to continuous expansion, and it will also be a golden period for the medical beauty industry to improve quality, enhance efficiency, and move towards high-quality development. With the steady recovery of service-oriented consumption, the Chinese medical beauty market is expected to grow by about 10% in 2024.
No Data
No Data